Experimental CAR-T therapy takes on tough lupus cases

NCT ID NCT06984341

Terminated Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 4 times

Summary

This early-stage trial tests a new treatment called P-CD19CD20-ALLO1, a type of CAR-T cell therapy, for people with severe lupus that hasn't improved with standard treatments. The study will enroll 162 participants and aims to check if the therapy is safe and tolerable. It also looks at how the cells behave in the body and whether they can reduce lupus activity, possibly leading to drug-free remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: P-CD19CD20-ALLO1 cells (a type of CAR-T cell therapy)
What this could lead to: If successful, this could lead to a new treatment option for people with severe lupus that hasn't responded to other therapies, potentially inducing long-term remission without ongoing medication.
What could go wrong: This is an early Phase 1 trial, so safety and effectiveness are not yet proven. There are risks of severe side effects from the cell therapy and chemotherapy, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

University of Alabama at Birmingham: The Kirklin Clinic

Birmingham, Alabama, 35233, United States
University of Iowa

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.